Evidence map›Paper›PMID 41181888›Full record

ArticleJournal of pediatric gastroenterology and nutrition2026

The validated French CFAbd-Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor.

Isabelle Sermet-Gaudelus, Pauline Sadrieh, Anne Sophie Bonnel, Raphael Enaud, Nathalie Wizla, Jeanne Languepin, Ambre Nangui, Audrey Deelawon, Johanna Rave, Samira Dabelow and 4 more

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Isabelle Sermet-GaudelusUniversité de Paris, Paris, France.
Pauline SadriehCystic Fibrosis Centre, Brandenburg Medical School (MHB) University, Klinikum Westbrandenburg, Brandenburg an der Havel, Germany.
Anne Sophie BonnelCentre de Référence Maladie Rare-Mucoviscidose, Hôpital Necker Enfants Malades, Paris, France.
Raphael EnaudCentre de Recherche Cardio-Thoracique de Bordeaux, Univ. Bordeaux, Bordeaux, France.
Nathalie WizlaCRCM Pédiatrique, Hôpital Jeanne de Flandre, Lille, France.
Jeanne LanguepinCRCM Pédiatrique, Centre Hospitalier Universitaire, Limoges, France.
Ambre NanguiCentre de Référence Maladie Rare-Mucoviscidose, Hôpital Necker Enfants Malades, Paris, France.
Audrey DeelawonCentre de Référence Maladie Rare-Mucoviscidose, Hôpital Necker Enfants Malades, Paris, France.
Johanna RaveCystic Fibrosis Centre, Brandenburg Medical School (MHB) University, Klinikum Westbrandenburg, Brandenburg an der Havel, Germany.
Samira DabelowCystic Fibrosis Centre, Brandenburg Medical School (MHB) University, Klinikum Westbrandenburg, Brandenburg an der Havel, Germany.
Anton BaruchaCystic Fibrosis Centre, Brandenburg Medical School (MHB) University, Klinikum Westbrandenburg, Brandenburg an der Havel, Germany.
Carlos ZagoyaCystic Fibrosis Centre, Brandenburg Medical School (MHB) University, Klinikum Westbrandenburg, Brandenburg an der Havel, Germany.ORCID https://orcid.org/0000-0002-1822-3750
Franziska DucksteinCystic Fibrosis Centre, Brandenburg Medical School (MHB) University, Klinikum Westbrandenburg, Brandenburg an der Havel, Germany.
Jochen Georg MainzCystic Fibrosis Centre, Brandenburg Medical School (MHB) University, Klinikum Westbrandenburg, Brandenburg an der Havel, Germany.ORCID https://orcid.org/0000-0003-3780-7759

Funding

Vertex Therapeutics
6 · The paper itself

Abstract

objectivesMultiorgan abdominal involvement is a hallmark of Cystic fibrosis (CF). The CFAbd-Score

methodsValidation was performed following two forward translations and a review process by a German professional medical translator. The reviewed consensus version was psychometrically evaluated for validity and reliability in French-speaking pwCF and HC cohorts, as well as in pwCF with and without ETI.

resultsA total of 64 French-speaking pwCF (mean age: 12.5 years) and 58 HC were included. Median CFAbd-Score

conclusionThe French version of the CFAbd-Score has proved to be reliable and sensitive to capture AS in French-speaking pwCF and to distinguish pwCF from HC. Furthermore, consistent with previous findings, the PROM sensitively detects ETI-related differences in AS of pwCF with and without ETI therapy, and thus can be used in research and clinical routine.

Indexed as

AminophenolsBenzodioxolesCystic FibrosisGastrointestinal DiseasesIndolesPatient Reported Outcome MeasuresPyrazolesPyridinesQuinolonesAdolescentAdultChildChloride Channel AgonistsDrug CombinationsFemaleFranceAminophenolsBenzodioxolesChloride Channel AgonistsDrug Combinationselexacaftorelexacaftor, ivacaftor, tezacaftor drug combinationIndolesivacaftorPyrazolesPyridinesPyrrolidinesQuinolinesQuinolonestezacaftor, ivacaftor drug combinationabdominal symptomsCFTRmodulator therapypatient‐reported outcome measurescoring

Identifiers

PMID41181888
PMCPMC12780474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.